NEWPORT NEWS, Va., Aug. 30, 2011 /PRNewswire/ — Dilon expands
its portfolio of breast imaging solutions through a sales alliance
with PenRad, rated #1 Mammography Information System technology by
KLAS for three consecutive years. Product innovation, high
quality and customer loyalty are the foundation of PenRad’s
success. Together Dilon and PenRad provide leading-edge breast
imaging tools, and an information management system that
significantly improves patient care, mammography workflow and
imaging center economics.
Dilon Diagnostics, recipient of the Frost & Sullivan
Molecular Breast Imaging Company of 2011 and the KLAS category
winner for Breast Specific Imaging Modalities 2010, is the market
leader for compact gamma cameras that support breast-specific gamma
imaging/molecular breast imaging (BSGI/MBI) studies. Dilon
optimizes the clinical results of BSGI/MBI, a procedure that sees
lesions independent of tissue density and provides a functional
imaging complement to the anatomical imaging of mammography.
BSGI/MBI is particularly useful for patients with equivocal
mammograms, dense breast tissue and for help with determining the
extent of disease.
With camera installations worldwide, Dilon is now expanding its
portfolio in women’s imaging to include the PenRad Mammography
Information System (MIS), and Volpara, a quantitative breast
density assessment tool that converts the qualitative breast x-ray
image into quantitative data. Breast tissue density has not only
been linked to an increased risk of breast cancer, it also
decreases the sensitivity of the mammogram and thereby may impact
early detection. Volpara is designed to assist radiologists by
objectively and automatically assessing a woman’s breast density,
and facilitates breast centers’ compliance with new legislation and
notification guidelines. PenRad automatically integrates the
information from Volpara and BSGI/MBI into the routine MIS
workflow.
PenRad has been pioneerin
‘/>”/>
